Short Interest in Relief Therapeutics Holding SA (OTCMKTS:RLFTF) Declines By 63.5%

Relief Therapeutics Holding SA (OTCMKTS:RLFTF) saw a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 7,692 shares, a decline of 63.5% from the April 15th total of 21,047 shares. Based on an average daily trading volume, of 4,461 shares, the days-to-cover ratio is currently 1.7 days.

Relief Therapeutics Price Performance

Shares of OTCMKTS RLFTF traded up $0.04 during midday trading on Friday, hitting $0.54. 1,856 shares of the company traded hands, compared to its average volume of 3,454. Relief Therapeutics has a 12-month low of $0.33 and a 12-month high of $4.88. The stock has a 50-day moving average price of $0.49 and a 200 day moving average price of $1.78.

About Relief Therapeutics

Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.

The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.